Valneva: Everyone should have access to technology best suited to protect them - Printable Version
+- SG Talk (https://sgtalk.net)
+-- Forum: SG Talk (https://sgtalk.net/Forum-SG-Talk)
+--- Forum: Market Talk (https://sgtalk.net/Forum-Market-Talk)
+--- Thread: Valneva: Everyone should have access to technology best suited to protect them (/Thread-Valneva-Everyone-should-have-access-to-technology-best-suited-to-protect-them)
+- SG Talk (https://sgtalk.net)
+-- Forum: SG Talk (https://sgtalk.net/Forum-SG-Talk)
+--- Forum: Market Talk (https://sgtalk.net/Forum-Market-Talk)
+--- Thread: Valneva: Everyone should have access to technology best suited to protect them (/Thread-Valneva-Everyone-should-have-access-to-technology-best-suited-to-protect-them)
Valneva: Everyone should have access to technology best suited to protect them - theold - 13-08-2021
https://www.pmlive.com/pharma_news/valnevas_covid-19_vaccine_to_be_tested_in_older_people_1374820
RE: Valneva: Everyone should have access to technology best suited to protect them - theold - 13-08-2021
Inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (manufactured as IXIARO) is the only JE vaccine licensed and available in the United States.
This vaccine was approved in March 2009 for use in people aged 17 years and older and in May 2013 for use in children 2 months through 16 years of age.
https://www.google.com/search?q=Japanese+encephalitis+vaccine&oq=Japanese+encephalitis+vaccine&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8